Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. The company called the ...

Julie Kim is set to replace Christophe Weber as the new chief executive officer of Takeda Pharmaceutical Co., becoming the first woman to lead the more than 240-year-old Japanese drugmaker.

Julie Kim is set to replace Christophe Weber as the new CEO of Takeda Pharmaceutical, becoming the first woman to lead the more than 240-year-old Japanese drugmaker. Kim, 54, has been running ...

Tokyo, Jan. 30 (Jiji Press)--Japan's Takeda Pharmaceutical Co. said Thursday that its president and CEO, Christophe Weber, will step down at its general shareholders meeting in June 2026.

Takeda Pharmaceutical 45020.69%increase; green up pointing triangle named Julie Kim, who heads its U.S. business, as its new chief executive starting in 2026, elevating her to the small but ...

TOKYO, Japan — Takeda Pharmaceuticals has named Julie Kim as the first woman to lead the 244-year-old Japanese drugmaker, a rarity in senior management in the world's fourth-largest economy. Kim, a US ...

Day One Biopharma's OJEMDA FDA approval for pediatric glioma, but market concerns remain. Check out why I rate DAWN stock as ...

Takeda has decided to withdraw its cancer drug Exkivity from the market, after a trial that was supposed to confirm its efficacy failed to deliver a positive result. Following discussions with the ...

Tekken' has prevailed over even 'Street Fighter' and 'Mortal Kombat' in creating a diverse space for players in a martial arts video game.

Takeda has had a run of bad luck with its Wave1 pipeline of new drug candidates of late, but can now celebrate a vestry after getting FDA approval for first-in-class lung cancer therapy Exkivity.

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...